Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.

For the purpose of screening individuals at high risk for coronary heart disease (CHD), serum total cholesterol (TC) of 5.2 mmol/L, has been set as a value dividing "desirable" from intermediate high or elevated levels, and HDL cholesterol (HDL-C) < 0.9 mmol/L has been labeled as abnormally low, implying high CHD risk. It has been conjectured that low HDL-C poses no risk in the absence of elevated LDL cholesterol or TC. To assess the risk of CHD-free men with "isolated low HDL-C," ie, abnormally low HDL-C with desirable TC, we examined the CHD and all-cause mortality of some 8000 Israeli men aged 42 years and older during 1965 through 1986. Men with isolated low HDL-C represented one sixth of the cohort. CHD mortality among these men was 36% higher (age adjusted) than in counterparts with desirable TC, of which > 0.9 mmol/L was contained in the high-density fraction. In men with TC > 5.2 mmol/L, abnormally low HDL-C was associated with a virtually identical CHD mortality risk ratio, 38%. These findings persisted after adjustment for multiple CHD risk factors. The excess CHD risk associated with isolated low HDL-C appeared particularly increased in men with diabetes mellitus, whose death rate was 65% higher than in diabetics with HDL-C > 0.9 mmol/L. A second subgroup result was consistent with equal CHD mortality risk among men in the "desirable" TC range, with or without low HDL-C, if systolic blood pressure was > 160 mm Hg. These are post hoc findings, and hypotheses arising from these observations would require independent examination. Total mortality was not increased in men with isolated low HDL-C compared with men who had HDL-C < 0.9 mmol/L and TC > 5.2 mmol/L at baseline. These results indicate that an increased risk of CHD death is associated with abnormally low HDL-C for cholesterol ranges both below and above 5.2 mmol/L. For the individual, therefore, the risk is multiplied by the same amount regardless of TC. Quitting smoking, increasing physical activity, and decreasing body weight would all contribute to raise HDL-C in individuals of most or all age groups. When examined from a community perspective, the results are consistent with a relatively low population-attributable fraction among CHD-free men. This would tend to support the recommended practice of considering a TC level of 5.2 mmol/L (200 mg/dL) as a threshold for further evaluation in screened individuals without manifest CHD.

[1]  U. Goldbourt,et al.  Influence of physical work on high density lipoprotein cholesterol: implications for the risk of coronary heart disease. , 1994, International journal of sports medicine.

[2]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[3]  E. Barrett-Connor,et al.  Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. , 1994, Circulation.

[4]  Robert Murphy,et al.  Socioeconomic Status and Coronary Heart Disease Risk Factor Trends The Minnesota Heart Survey , 1993, Circulation.

[5]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[6]  U. Goldbourt,et al.  Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). , 1993, The American journal of cardiology.

[7]  M. Miller,et al.  Long‐term Predictors of Subsequent Cardiovascular Events With Coronary Artery Disease and ‘Desirable’ Levels of Plasma Total Cholesterol , 1992, Circulation.

[8]  F. Sacks Desirable serum total cholesterol with low HDL cholesterol levels. An undesirable situation in coronary heart disease. , 1992, Circulation.

[9]  L. Wilkins Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. , 1992, Circulation.

[10]  U. Goldbourt,et al.  Cholesterol and coronary heart disease mortality. A 23-year follow-up study of 9902 men in Israel. , 1990, Arteriosclerosis.

[11]  K. Vranizan,et al.  Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. , 1988, The New England journal of medicine.

[12]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[13]  M. Taskinen,et al.  Alcohol-induced changes in serum lipoproteins and in their metabolism. , 1987, American heart journal.

[14]  U. Goldbourt,et al.  ASSOCIATIONS OF SERUM HIGH DENSITY LIPOPROTEIN AND TOTAL CHOLESTEROL WITH TOTAL, CARDIOVASCULAR, AND CANCER MORTALITY IN A 7-YEAR PROSPECTIVE STUDY OF 10 000 MEN , 1981, The Lancet.

[15]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[16]  E. H. Strisower,et al.  Treatment of hyperlipidemias. , 1968, The American journal of medicine.

[17]  J. Medalie,et al.  An epidemiologic investigation of hypertension and ischemic heart disease within a defined segment of the adult male population of Israel. , 1968, Israel journal of medical sciences.

[18]  M. Burstein,et al.  Sur un dosage rapide du cholesterol lié aux α-et aux β-lipoprotéines du sérum , 1960 .

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  D. Rader,et al.  Lipids, Apolipoproteins and Lipoproteins , 1994 .

[21]  U. Goldbourt,et al.  Genetic factors in coronary heart disease , 1994, Developments in Cardiovascular Medicine.

[22]  J. Medalie,et al.  Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. , 1993, Cardiology.

[23]  D. Gordon,et al.  Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. , 1993, The American journal of cardiology.

[24]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[25]  U. Goldbourt,et al.  A SAS program for evaluating person-years of risk in cohort studies. , 1989, Computers in biology and medicine.

[26]  K. Namboodiri,et al.  Biological and cultural sources of familial resemblance in plasma lipids: A comparison between North America and Israel—the lipid research clinics program , 1988, Genetic epidemiology.

[27]  J. Medalie,et al.  Characteristics of smokers, non-smokers and ex-smokers among 10,000 adult males inIsrael. II. Physiologic, biochemical and genetic characteristics. , 1977, American journal of epidemiology.

[28]  D. Cox Regression Models and Life-Tables , 1972 .